JP2019131579A5 - - Google Patents

Download PDF

Info

Publication number
JP2019131579A5
JP2019131579A5 JP2019070293A JP2019070293A JP2019131579A5 JP 2019131579 A5 JP2019131579 A5 JP 2019131579A5 JP 2019070293 A JP2019070293 A JP 2019070293A JP 2019070293 A JP2019070293 A JP 2019070293A JP 2019131579 A5 JP2019131579 A5 JP 2019131579A5
Authority
JP
Japan
Prior art keywords
crystal
mixture
hemisulfate
following
represented
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019070293A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019131579A (ja
JP6764501B2 (ja
Filing date
Publication date
Priority claimed from EP13004050.4A external-priority patent/EP2837631A1/en
Application filed filed Critical
Publication of JP2019131579A publication Critical patent/JP2019131579A/ja
Publication of JP2019131579A5 publication Critical patent/JP2019131579A5/ja
Application granted granted Critical
Publication of JP6764501B2 publication Critical patent/JP6764501B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019070293A 2013-08-14 2019-04-02 5,10−メチレン−(6r)−テトラヒドロ葉酸のヘミ硫酸塩 Active JP6764501B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13004050.4 2013-08-14
EP13004050.4A EP2837631A1 (en) 2013-08-14 2013-08-14 New stable salt of 5,10-methylene-(6R)-tetrahydrofolic acid

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2016533926A Division JP6617104B2 (ja) 2013-08-14 2014-08-14 5,10−メチレン−(6r)−テトラヒドロ葉酸のヘミ硫酸塩

Publications (3)

Publication Number Publication Date
JP2019131579A JP2019131579A (ja) 2019-08-08
JP2019131579A5 true JP2019131579A5 (enExample) 2020-01-09
JP6764501B2 JP6764501B2 (ja) 2020-09-30

Family

ID=48998397

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2016533926A Active JP6617104B2 (ja) 2013-08-14 2014-08-14 5,10−メチレン−(6r)−テトラヒドロ葉酸のヘミ硫酸塩
JP2018164332A Active JP6735321B2 (ja) 2013-08-14 2018-09-03 5,10−メチレン−(6r)−テトラヒドロ葉酸のヘミ硫酸塩
JP2019070293A Active JP6764501B2 (ja) 2013-08-14 2019-04-02 5,10−メチレン−(6r)−テトラヒドロ葉酸のヘミ硫酸塩
JP2020083208A Active JP7396960B2 (ja) 2013-08-14 2020-05-11 5,10-メチレン-(6r)-テトラヒドロ葉酸のヘミ硫酸塩
JP2021183793A Active JP7710356B2 (ja) 2013-08-14 2021-11-11 5,10-メチレン-(6r)-テトラヒドロ葉酸のヘミ硫酸塩

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2016533926A Active JP6617104B2 (ja) 2013-08-14 2014-08-14 5,10−メチレン−(6r)−テトラヒドロ葉酸のヘミ硫酸塩
JP2018164332A Active JP6735321B2 (ja) 2013-08-14 2018-09-03 5,10−メチレン−(6r)−テトラヒドロ葉酸のヘミ硫酸塩

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020083208A Active JP7396960B2 (ja) 2013-08-14 2020-05-11 5,10-メチレン-(6r)-テトラヒドロ葉酸のヘミ硫酸塩
JP2021183793A Active JP7710356B2 (ja) 2013-08-14 2021-11-11 5,10-メチレン-(6r)-テトラヒドロ葉酸のヘミ硫酸塩

Country Status (27)

Country Link
US (4) US20160185787A1 (enExample)
EP (3) EP2837631A1 (enExample)
JP (5) JP6617104B2 (enExample)
KR (2) KR102410373B1 (enExample)
CN (2) CN108096200A (enExample)
AU (2) AU2014307872B2 (enExample)
BR (2) BR112016002770B1 (enExample)
CA (1) CA2921178C (enExample)
CY (2) CY1119694T1 (enExample)
DK (2) DK3287460T3 (enExample)
EA (3) EA201892729A1 (enExample)
ES (2) ES2654474T3 (enExample)
HK (1) HK1256262A1 (enExample)
HR (2) HRP20171895T1 (enExample)
HU (2) HUE037615T2 (enExample)
IL (2) IL244069B (enExample)
LT (2) LT3287460T (enExample)
MX (2) MX382578B (enExample)
NO (1) NO3033344T3 (enExample)
NZ (2) NZ745811A (enExample)
PL (2) PL3033344T3 (enExample)
PT (2) PT3033344T (enExample)
RS (2) RS61986B1 (enExample)
SG (2) SG10201801179VA (enExample)
SI (2) SI3033344T1 (enExample)
WO (1) WO2015022407A1 (enExample)
ZA (1) ZA201509204B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2837631A1 (en) * 2013-08-14 2015-02-18 Merck & Cie New stable salt of 5,10-methylene-(6R)-tetrahydrofolic acid
US10059710B2 (en) 2016-02-17 2018-08-28 Merck & Cie Stable formulations of 5,10-methylene-(6R)-tetrahydrofolic acid
EP3446703A1 (en) * 2017-08-24 2019-02-27 Isofol Medical AB 6r]-mthf multiple bolus administration in 5-fluorouracil based chemotherapy
EP3446704A1 (en) * 2017-08-24 2019-02-27 Isofol Medical AB [6r]-mthf - an efficient folate alternative in 5-fluorouracil based chemotherapy
ES2902051T3 (es) * 2017-08-16 2022-03-24 Merck Patent Gmbh Liofilizados estables que contienen ácido 5,10-metilen-(6R)-tetrahidrofólico y un ácido dicarboxílico
CN110573178A (zh) * 2018-01-05 2019-12-13 伊索弗尔医药公司 治疗结直肠癌和转移性结直肠癌的方法
CN115335740A (zh) * 2020-03-30 2022-11-11 住友化学株式会社 层叠体
KR20250022144A (ko) 2022-06-08 2025-02-14 메르크 파텐트 게엠베하 5,10-메틸렌-(6R)-테트라히드로폴산 및 NACl을 포함하는 안정한 약학적 조성물
CN119343131A (zh) 2022-06-08 2025-01-21 默克专利股份有限公司 包含5,10-亚甲基-(6r)-四氢叶酸钠的浓缩溶液
WO2023237483A1 (en) 2022-06-08 2023-12-14 Merck Patent Gmbh Concentrated solutions comprising 5,10-methylene-(6r)-tetrahydrofolic acid
AU2023282347A1 (en) 2022-06-08 2025-01-16 Merck Patent Gmbh Compositions comprising disodium 5,10-methylene-(6r)-tetrahydrofolate
WO2023237485A1 (en) 2022-06-08 2023-12-14 Merck Patent Gmbh Stable lyophilisates comprising 5,10-methylene-(6r)-tetrahydrofolic acid

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2300505A (en) * 1940-10-31 1942-11-03 Bell Telephone Labor Inc Selective system
AU575814B2 (en) 1983-03-03 1988-08-11 Bengt Gustavsson A device for transferring a substance
DE3821875C1 (enExample) * 1988-06-29 1990-02-15 Eprova Ag, Forschungsinstitut, Schaffhausen, Ch
CH682664A5 (en) * 1991-10-15 1993-10-29 Eprova Ag Stable salts of 5,10-methylene tetrahydrofolate.
CH684644A5 (de) 1992-07-13 1994-11-15 Eprova Ag 5,10-Methylentetrahydrofolsäure-Cyclodextrin-Einschlussverbindungen.
HU226998B1 (en) * 2000-11-23 2010-04-28 Richter Gedeon Nyrt Desloratadine hemisulphate, process for the preparation thereof and pharmaceutical compositions containing the same
CH696628A5 (de) 2002-02-26 2007-08-31 Eprova Ag Verwendung von Folaten zur Herstellung einer Zubereitung geeignet zur Vorbeugung und Behandlung von Entzündungen und entzündungsassoziierter Krankheiten, im Speziellen zur Beeinflussung der
CH697021A5 (de) * 2003-06-26 2008-03-31 Merck Eprova Ag Stabile pharmazeutische Zusammensetzungen von 5, 10-Methylentetrahydrofolat.
KR20080074201A (ko) 2005-12-02 2008-08-12 어드벤트륵스 파마슈티칼스, 인크. 5,10 메틸렌테트라히드로폴레이트의 안정한 약학 조성물
HRP20160950T1 (hr) 2006-12-21 2016-10-07 F. Hoffmann-La Roche Ag Polimorfi antagonista mglur5 receptora
JP5294968B2 (ja) 2009-05-01 2013-09-18 三星ダイヤモンド工業株式会社 スクライブヘッド及び該スクライブヘッドを用いたスクライブ装置
BR112014009634A2 (pt) * 2011-10-19 2017-05-09 Mercator Medsystems Inc preparação e agente terapêutico
EP2837766A1 (de) * 2013-08-14 2015-02-18 Sika Technology AG Verfahren zum Ausfüllen einer Fuge mit einem Kleb- und/oder Dichtstoff sowie System zum Ausfüllen einer Fuge mit einem Kleb- und/oder Dichtstoff
EP2837631A1 (en) * 2013-08-14 2015-02-18 Merck & Cie New stable salt of 5,10-methylene-(6R)-tetrahydrofolic acid
JP6971761B2 (ja) * 2017-10-11 2021-11-24 株式会社Ihiプラント タンクの構築方法

Similar Documents

Publication Publication Date Title
JP2019131579A5 (enExample)
US10202353B2 (en) Therapeutic compounds
JP2016528242A5 (enExample)
JP2012516900A5 (enExample)
CN110573500A (zh) N-(氮杂芳基)环内酰胺-1-甲酰胺衍生物及其制备方法和应用
CN119454711A (zh) 被取代的吡啶酮-吡啶基化合物的方法、组合物和结晶形式
JPWO2021245055A5 (enExample)
JP2006523216A5 (enExample)
CA2575720A1 (en) Pyrimidine derivatives
JP2016537346A5 (enExample)
CN107674056B (zh) 芹菜素衍生物其在治疗高尿酸血症中的应用
ES2825348T3 (es) Compuestos y composición farmacéutica asociados al sistema ubiquitinación-proteasoma
CN100344611C (zh) 4-硝基-2-[(4′-甲氧基)-苯氧基]-甲磺酰苯胺衍生物及其医药用途
TW201513864A (zh) 含低用量伊立替康鹽酸鹽水合物之抗腫瘤劑
SI3033344T1 (en) CHEMISULPHATE SOL 5,10-METHYLENE- (6R) -THETRAHYDROPHOLIC ACID
CN115315423A (zh) 取代芳基类化合物
US10709697B2 (en) Bis-amines, compositions, and uses related to CXCR4 inhibition
CN115135649A (zh) 包括吡啶并[1,2-a]嘧啶酮化合物的药物组合
MX2022006990A (es) Forma cristalina de un derivado del acido 7h-benzo[7]anuleno-2-car boxilico.
JP2005519912A (ja) プテリジン誘導体、その製造方法、およびその使用法
US10947225B2 (en) Phosphotidylinositol 3-kinase inhibitors
CN101484443A (zh) 放射线治疗增强剂
CN114423762A (zh) 大环类衍生物及其制备方法和用途
JP2009517353A5 (enExample)
AU2004220205B2 (en) Antitumor effect potentiator and antitumor agent